When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CBAY - CymaBay up 7% on new seladelpar data in bile duct disorder
CymaBay Therapeutics Inc.
CymaBay Therapeutics (CBAY+7.1%) perks up, albeit on below-average volume, on the heels of new data from a previously completed open-label Phase 2 clinical trial evaluating seladelpar in patients with primary biliary cholangitis (PBC), an autoimmune disorder characterized by the progressive destruction of the liver's bile ducts. The results were presented virtually at Digestive Disease Week.
More news on: CymaBay Therapeutics, Inc., Healthcare stocks news, Stocks on the move,